Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 4/20 | 0.41 |
| ▸ | DRD2 | P14416 | 5/20 | 0.37 |
| ▸ | DRD3 | P35462 | 5/20 | 0.37 |
| ▸ | DRD1 | P21728 | 3/20 | 0.37 |
| ▸ | DRD4 | P21917 | 3/20 | 0.37 |
| ▸ | DRD5 | P21918 | 3/20 | 0.37 |
| ▸ | STS | P08842 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.36 |
| ▸ | AR | P10275 | 2/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
| ▸ | HTR1D | P28221 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14253999 | 0.85 | GAA (0.44) | VDRDRD2DRD3DRD1DRD4 | |
| SCHEMBL5156307 | 0.83 | AR (0.50) | VDRDRD2DRD3DRD1DRD4 | |
| SCHEMBL1525824 | 0.83 | ESR1 (0.58) | VDRARESR1ESR2 | |
| SCHEMBL2976823 | 0.81 | FFAR4 (0.45) | VDRMRGPRX4 | |
| SCHEMBL13857578 | 0.80 | VDR (0.42) | VDRDRD2DRD3DRD1DRD4 | |
| SCHEMBL29492903 | 0.80 | MAPK1 (0.41) | VDRDRD2DRD3DRD1DRD4 | |
| SCHEMBL20556401 | 0.80 | MAPK1 (0.41) | VDRDRD2DRD3DRD1DRD4 | |
| SCHEMBL2979160 | 0.79 | ESR1 (0.46) | VDRSTSHDAC6HDAC3AR | |
| SCHEMBL5153949 | 0.79 | VDR (0.50) | VDRHDAC6HDAC3AR | |
| SCHEMBL5159141 | 0.79 | VDR (0.41) | VDRDRD2DRD3DRD1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1740522-A2 | BISPHENYL COMPOUNDS USEFUL AS VITAMIN D SB 3 /SB RECEPTOR AGONISTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-01-10 | — | — | EP | disclosed |
| US-20060025474-A1 | Bisphenyl compounds useful as vitamin D3 receptor agonists | CHUGAI SEIYAKU KABUSHIKA KAISHA (JP) | 2006-02-02 | — | — | US | disclosed |
| WO-2005087700-A2 | BISPHENYL COMPOUNDS USEFUL AS VITAMIN D3 RECEPTOR AGONISTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025474-A1 | Bisphenyl compounds useful as vitamin D3 receptor agonists | VDR, CYP2R1, CYP24A1 | VDR 1/4885DRD2 112/4885DRD3 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.